CEBPA and acute myeloid leukemia: Our results, generated in the largest cohorts of patients with CEBPA mutant AML reported so far, strongly support the notion that the CEBPA bZIPInDel genotype introduced in this work (bZIP in-frame insertions/deletions, double and single mutant) shows a specific biology and favorable prognostic implications, whereas the other CEBPA mutational subgroups, i.e. TAD mutations as well as bZIP missense and frameshift/nonsense mutations, differ substantially with respect to most clinical as well as molecular factors studied.